RT Book, Section
A1 Kiel, Patrick J.
A1 Fausel, Christopher A.
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1150336130
T1 Chronic Leukemias
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1150336130
RD 2024/04/24
AB Content  UpdateDecember  12,  2017Long-Term  Outcomes  of  Imatinib  (Gleevec®)  Treatment  for  Chronic  Myeloid  Leukemia:  A  follow-up  study  reported  the  long-term  outcomes  of  the  phase  3  International  Randomized  Study  of  Interferon  and  STI571  (IRIS)  trial,  which  showed  that  imatinib  was  more  effective  and  better  tolerated  than  interferon  alfa  plus  low-dose  cytarabine  in  patients  with  newly-diagnosed  chronic  myeloid  leukemia  (CML)  in  the  chronic  phase.  The  follow-up  study  evaluated  patients  who  had  been  randomized  to  receive  imatinib;  overall  survival  at  10  years  was  83.3%  with  a  median  follow-up  of  10.9  years.  The  discontinuation  rate  of  imatinib  due  to  adverse  events  (6.9%)  was  much  lower  than  the  interferon  alfa  plus  cytarabine  study  arm  (26.2%).  These  results  show  that  the  efficacy  of  imatinib  400  mg  daily  is  maintained  with  a  tolerable  safety  profile;  imatinib  and  the  second-generation  tyrosine  kinase  inhibitors  dasatinib  and  nilotinib  are  recommended  as  first-line  therapy  for  patients  with  CML  in  chronic  phase.